Overview

TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether an intravitreal dexamethasone implant (Ozurdex, Allergan) is effective to manage macular edema secondary to non-infectious uveitis.
Phase:
Phase 4
Details
Lead Sponsor:
Northern California Retina Vitreous Associates
Collaborator:
Allergan
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate